- Home
- TNYA vs EPIX Comparison
TNYA vs EPIX Comparison
Compare TNYA & EPIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNYA
- EPIX
- Stock Information
- Founded
- TNYA 2016
- EPIX 2009
- Country
- TNYA United States
- EPIX Canada
- Employees
- TNYA N/A
- EPIX N/A
- Industry
- TNYA Medicinal Chemicals and Botanical Products
- EPIX Biotechnology: Pharmaceutical Preparations
- Sector
- TNYA Health Care
- EPIX Health Care
- Exchange
- TNYA Nasdaq
- EPIX Nasdaq
- Market Cap
- TNYA 189.1M
- EPIX 9.1M
- IPO Year
- TNYA 2021
- EPIX N/A
- Fundamental
- Price
- TNYA $1.22
- EPIX $0.20
- Analyst Decision
- TNYA Strong Buy
- EPIX Hold
- Analyst Count
- TNYA 5
- EPIX 3
- Target Price
- TNYA $8.60
- EPIX $2.00
- AVG Volume (30 Days)
- TNYA 3.0M
- EPIX 15.7M
- Earning Date
- TNYA 11-05-2025
- EPIX 08-13-2025
- Dividend Yield
- TNYA N/A
- EPIX N/A
- EPS Growth
- TNYA N/A
- EPIX N/A
- EPS
- TNYA N/A
- EPIX N/A
- Revenue
- TNYA N/A
- EPIX N/A
- Revenue This Year
- TNYA N/A
- EPIX N/A
- Revenue Next Year
- TNYA N/A
- EPIX N/A
- P/E Ratio
- TNYA N/A
- EPIX N/A
- Revenue Growth
- TNYA N/A
- EPIX N/A
- 52 Week Low
- TNYA $0.36
- EPIX $0.19
- 52 Week High
- TNYA $4.01
- EPIX $7.41
- Technical
- Relative Strength Index (RSI)
- TNYA 56.83
- EPIX 7.66
- Support Level
- TNYA $1.15
- EPIX $0.19
- Resistance Level
- TNYA $1.43
- EPIX $0.21
- Average True Range (ATR)
- TNYA 0.10
- EPIX 0.02
- MACD
- TNYA -0.02
- EPIX 0.02
- Stochastic Oscillator
- TNYA 44.74
- EPIX 24.25
About TNYA Tenaya Therapeutics Inc.
Tenaya Therapeutics Inc is a preclinical stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. It is advancing product candidates from three product platforms: gene therapy, cellular regeneration and precision medicine.
About EPIX ESSA Pharma Inc.
ESSA Pharma Inc is a pharmaceutical company. The company was focused on the development of small-molecule drugs for the treatment of castration-resistant prostate cancer. It was developing drugs that selectively block the amino-terminal domain of the androgen receptor, potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients with the potential for increased progression-free and overall survival. Currently, the company has terminated its clinical trials and other studies.